PIONEER 6 achieved its primary objective, confirming noninferiority for oral semaglutide versus placebo for cardiovascular safety in a high-risk population, with a non-significant 21 percent reduction in three-point MACE over a median follow-up period of just under 16 months, said lead investigator Mansoor Husain, MD, Director of the Toronto General Hospital Research Institute, Executive Director of the Ted Rogers Centre for Heart Research, and Professor of Medicine at the University of Toronto
CagriSema expands the field beyond GLP-1 alone: Novo Nordisk's cagrilintide/semaglutide combination pairs an amylin analog with a GLP-1 receptor agonist
Both Ozempic and HCG can have side impacts, in spite of the fact that they vary in severity and frequency
Many people on GLP-1 medications feel uncomfortable after eating large meals
Why Choose TrimBody M.D
Equally importantly, GLP-1 receptor agonist use was associated with some increased risks compared to usual care with other treatments